---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-25-000021"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:53:00.388455+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027

## Summary
- Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.
- Cash, cash equivalents, and investments $152.4M as of March 31, 2025, up from $98.6M at Dec 31, 2024.
- Guidance: cash sufficient to fund operations into Q4 2027.
- Phase 2 data for BDTX-1535 in 1L NSCLC expected Q4 2025; FDA feedback on pivotal path planned.
- Global licensing agreement with Servier for BDTX-4933 includes $70M upfront and up to $710M in milestones plus royalties.

## SEC filing metadata
- accession: 0001701541-25-000021
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000021/0001701541-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000021/bdtx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-25-000021
- JSON: https://secwatch.observer/filing/0001701541-25-000021.json
- Plain text: https://secwatch.observer/filing/0001701541-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.